E7: The Outlook for Pharmaceuticals to 2012

The emerging E7 countries represent the best prospect for growth. The potential of these countries is huge: they have a combined population of over three billion people, and their economies are performing very well. One consequence of this increasing wealth is a growing financial capacity to treat previously unmet health needs. Another is increasing incidence of 'affluence' diseases such as diabetes, as people live longer and have more sedentary lifestyles. Browse All: Pharmaceutical Market Research Report Highlights from the reports. BRAZILrnThe Brazilian pharmaceutical market is the third largest in the Americas region, behind the USA and Canada; it ranks first in the Latin American region. Pharmaceutical demand will continue, fuelled by increasing disposable income, therefore the market outlook is positive for the 2011-2016 period. Higher consumption of patented and bioequivalent medicines in Brazil will continue, replacing consumption of similar medicines. CHINArnThe MoH has made lower medicine prices a top priority for health authorities in 2011. The National Development and Reform Commission (NDRC) reduced the prices of 162 drugs, by an average of 21.0%, effective from 28th March 2011. INDIArnThe Indian pharmaceutical market is highly competitive and remains dominated by low priced, domestically-produced generics. Despite having the second largest population in the world and a growing middle class with high healthcare expectations, India accounts for less than 2% of the world pharmaceutical market in value terms. In one of the world's better performing economies, spending on pharmaceuticals accounts for less than 1% of GDP and average per capita spending remains one of the lowest levels in the region. rnINDONESIArnDue to the sheer size of the population, Indonesia cannot simply be dismissed. The Indonesian pharmaceutical market is projected to grow at a low double-digit CAGR in US dollar terms during the forecast period, and it will be the sixth largest pharmaceutical market in the Asia Pacific region by 2016. There are around 240 domestic pharmaceutical manufacturers in Indonesia, with the vast majority located in Java. MEXICOrnThe pharmaceutical market in Mexico remains the second most attractive in Latin America. The Economist Intelligence Unit (EIU) projects a weak exchange rate for the Mexican peso in the forecast period, which will affect the value of the Mexican pharmaceutical market in US dollar terms. The CAGR will be moderate between 2011 and 2016. RUSSIArnRussia accounts for just under a third of the total Central & Eastern European pharmaceutical market, due to its population of 142 million; however, in per capita terms, Russia is also one of the smallest markets, compared to Romania. Over the last few years, import growth has been boosted by the federal drug supply system (DLO). TURKEYrnTurkey accounts for around 42% the total Middle Eastern pharmaceutical market, due to its population and GDP. The Turkish pharmaceutical market is expected to grow by a moderate CAGR in US dollar terms between 2011 and 2016. Related Reports: The Outlook for Pharmaceuticals in Central Asia World Medical Market Forecasts to 2016